Go Back

Literature in Oncology: Endocrine Tumours


PDFNeuroendocrine Tumors: A Comprehensive Guide to Diagnosis and Management

Authors: Aaron I. Vinik, MD, PhD, Thomas M. O’Dorisio, MD, Eugene A. Woltering, MD, Vay Liang W. Go, MD

Inter Science Institute

The GI Council of Inter Science Institute presents this comprehensive guide to diagnosis and management of neuroendocrine tumors to provide information and inspiration to all levels of clinicians, from novices to those professionally engaged in the field of neuroendocrine research, treatment, and analyses. This guidebook adds the new dimension of patient monitoring, not only through powerfully discriminating assays but through the recognition of clinical presentations and syndromes.

Avram AM.

Radioiodine Scintigraphy with SPECT/CT: An Important Diagnostic Tool for Thyroid Cancer Staging and Risk Stratification.

J Nucl Med Technol. 2014 Sep;42(3):170-180.


Giovanella L, Clark PM, Chiovato L, Duntas L, Elisei R, Feldt-Rasmussen U, Leenhardt L, Luster M, Schalin-Jäntti C, Schott M, Seregni E, Rimmele H, Smit J, Verburg FA.

Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper.

Eur J Endocrinol. 2014 Aug;171(2):R33-46.


PDFFree pdf

de Herder WW.

GEP-NETS update: functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs).

Eur J Endocrinol. 2014 Apr 10;170(5):R173-83.


PDFFree pdf

Ota N, Kato K, Iwano S, Ito S, Abe S, Fujita N, Yamashiro K, Yamamoto S, Naganawa S.

Comparison of ¹⁸F-fluoride PET/CT, ¹⁸F-FDG PET/CT and bone scintigraphy (planar and SPECT) in detection of bone metastases of differentiated thyroid cancer: a pilot study.

Br J Radiol. 2014 Feb;87


Trybek T, Kowalska A, Lesiak J, Młynarczyk J.

The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.

Nucl Med Rev Cent East Eur. 2014;17(2):87-93.


Blanchet EM, Martucci V, Millo C, Chen CC, Herscovitch P, Pacak K.

Multitracer PET imaging of bone metastases from paraganglioma: peripheral halo of uptake on 18F-FLT PET mismatching with central uptake of 18F-FDOPA, 18F-fluorodopamine, and 18F-FDG.

Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1928-9.


Sowa-Staszczak A, Lenda-Tracz W, Tomaszuk M, Głowa B, Hubalewska-Dydejczyk A.

Optimization of image reconstruction method for SPECT studies performed using [⁹⁹mTc-EDDA/HYNIC] octreotate in patients with neuroendocrine tumors.

Nucl Med Rev Cent East Eur. 2013;16(1):9-16.


PDFFree pdf

Taïeb D, Neumann H, Rubello D, Al-Nahhas A, Guillet B, Hindié E.

Modern nuclear imaging for paragangliomas: beyond SPECT.

J Nucl Med. 2012 Feb;53(2):264-74.


PDFFree pdf

Teunissen JJ, Kwekkeboom DJ, Valkema R, Krenning EP.

Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.

Endocr Relat Cancer. 2011 Oct 17;18 Suppl 1:S27-51.


PDFFree pdf

Melzer HI, Coppenrath E, Schmid I, Albert MH, von Schweinitz D, Tudball C, Bartenstein P, Pfluger T.

¹²³I-MIBG scintigraphy/SPECT versus ¹⁸F-FDG PET in paediatric neuroblastoma.

Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1648-58.


Giammarile F, Billotey C, Lombard-Bohas C, Le Bars D, Bournaud C, Masson S, Walter T, Houzard C, Scoazec JY, Hervieu V, Vuillez JP, Cornu C, Janier M, Borson-Chazot F.

18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours.

Nucl Med Commun. 2011 Feb;32(2):91-7.


Mustafa M, Kuwert T, Weber K, Knesewitsch P, Negele T, Haug A, Linke R, Bartenstein P, Schmidt D.

Regional lymph node involvement in T1 papillary thyroid carcinoma: a bicentric prospective SPECT/CT study.

Eur J Nucl Med Mol Imaging. 2010 Aug;37(8):1462-6.


Dudczak R, Traub-Weidinger T.

PET and PET/CT in endocrine tumours.

Eur J Radiol. 2010 Mar;73(3):481-93.


Kizu H, Takayama T, Tsushima H, Noguchi A, Nakajima K, Onoguchi M, Kinuya S.

Localization of metastases from malignant pheochromocytoma in patients undergoing 131I-MIBG therapy with manually fused 123I-MIBG SPECT and CT images.

J Nucl Med Technol. 2008 Dec;36(4):186-8.


Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A.

Gastroenteropancreatic neuroendocrine tumours.

Lancet Oncol. 2008 Jan;9(1):61-72. doi: 10.1016/S1470-2045(07)70410-2.


Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB.

The diagnosis and management of malignant phaeochromocytoma and paraganglioma.

Endocr Relat Cancer. 2007 Sep;14(3):569-85.


PDFFree pdf

Schipper ML, Riese CG, Seitz S, Weber A, Béhé M, Schurrat T, Schramm N, Keil B, Alfke H, Behr TM.

Efficacy of 99mTc pertechnetate and 131I radioisotope therapy in sodium/iodide symporter (NIS)-expressing neuroendocrine tumors in vivo.

Eur J Nucl Med Mol Imaging. 2007 May;34(5):638-50. Epub 2006 Dec 8.


Rufini V, Calcagni ML, Baum RP.

Imaging of neuroendocrine tumors.

Semin Nucl Med. 2006 Jul;36(3):228-47.


Giammarile F, Houzard C, Bournaud C, Hafdi Z, Sassolas G, Borson-Chazot F.

Diagnostic management of suspected metastatic thyroid carcinoma: clinical value of octreotide scintigraphy in patients with negative high-dose radioiodine scans.

Eur J Endocrinol. 2004 Mar;150(3):277-83.


Giammarile F, Hafdi Z, Bournaud C, Janier M, Houzard C, Desuzinges C, Itti R, Sassolas G, Borson-Chazot F.

Is [18F]-2-fluoro-2-deoxy-d-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake?

Eur J Endocrinol. 2003 Oct;149(4):293-300.


Lu G, Shih WJ, Xiu JY.

Technetium-99m MIBI uptake in recurrent parathyroid carcinoma and brown tumors.

J Nucl Med. 1995 May;36(5):811-3.


PDFFree pdf